Evidence map›Paper›PMID 42549255›Full record

ArticleTaiwan journal of ophthalmology

Retinopathy of prematurity epidemiology and treatment trend in a tertiary medical center in Taiwan: From 2016 to 2023.

Yi-Hsuan Tseng, Pei-Liang Wu, Eugene Yu-Chuan Kang, Kuan-Jen Chen, Nan-Kai Wang, Laura Liu, Hung-Da Chou, Ming-Chih Ho, Shih-Ming Chu, Yih-Shiou Hwang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yi-Hsuan TsengDepartment of Medicine, Mackay Medical University, Taipei, Taiwan.
Pei-Liang WuDepartment of Medicine, National Taiwan University, Taipei, Taiwan.
Eugene Yu-Chuan KangCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Kuan-Jen ChenCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Nan-Kai WangCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Laura LiuCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Hung-Da ChouCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Ming-Chih HoDepartment of Ophthalmology, Jen-Ai Hospital, Taichung, Taiwan.
Shih-Ming ChuCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Yih-Shiou HwangCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chi-Chun LaiCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Ming-Chou ChiangCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.
Wei-Chi WuCollege of Medicine, Chang Gung University, Taoyuan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the recent 8-year epidemiology of retinopathy of prematurity (ROP) and treatment modalities in Taiwan. MATERIALS AND

methodsA retrospective study was conducted from 2016 to 2023, using data from Chang Gung Memorial Hospital, Linkou, Taiwan, and enrolling 2078 premature babies who were screened for ROP. The incidence of ROP, type 1 ROP, and initial treatment were analyzed.

resultsROP developed in 671 of the 2078 infants (29.7%), and type 1 ROP was present in 195 infants (9.4%). A declining trend was observed in the number of ROP screenings among premature infants (

conclusionThe incidence of ROP between 2016 and 2023 showed no significant change. The proportion of type 1 ROP decreased during this period. Anti-VEGF was chosen as the initial treatment, and bevacizumab was the most frequently used agent.

Indexed as

Anti-vascular endothelial growth factorepidemiologylaserretinopathy of prematuritytreatment

Identifiers

PMID42549255
PMCPMC13431199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.